Efficacy
deaths, death, tumor
MAY, DISEASE, DISEASE PROGRESSION, TUMOR
In the ITT population, 1460 (73%) deaths occurred by the time of May 29, 2020, with a median follow-up time of 4.2 months. Median OS was 5.8 months (95% CI 5.4–6.1) (Fig. Kaplan–Meier analysis of overall survival (At the time of the efficacy analysis, 1272 (63%) patients experienced disease progression or death. The median PFS was 2.7 months (95% CI 2.2–2.8), with PFS at 3 and 6 months of 42.6% (95% CI 40.0–45.2) and 20.4% (95% CI 18.2–22.7), respectively. Four patients achieved complete response, 85 patients achieved partial response, and 629 patients had stable disease, with an ORR of 4.4% (95% CI 3.6–5.4) and a DCR of 35.8% (95% CI 33.7–38.0). In order to determine the effect of apatinib on tumor size, the response was also evaluated in patients with target lesions at baseline, providing an ORR of 5.5% (95%CI 4.4–6.7) and a DCR of 38.3% (95% CI 35.9–40.7), respectively.Efficacy in terms of OS and PFS was generally comparable between patients with an initial dose of ≤ 500 mg and those with > 500 mg. Median OS was 5.7 months (95% CI 5.4–6.1) for ≤ 500 mg and 6.1 months (95% CI 4.4–7.0) for > 500 mg. Median PFS was 2.6 months (95% CI 2.2–2.8) for ≤ 500 mg and 2.7 months (95% CI 1.9–3.3) for > 500 mg. Meanwhile, the OS of patients with a daily exposure dose of ≤ 500 mg was almost similar to those with > 500 mg (Fig. Subgroup analyses of overall survival according to initial dose (